All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Dengue is a systemic viral disease, and the main vector of epidemiological importance in the transmission of dengue virus (DENV) is *Aedes aegypti* \[[@pone.0211401.ref001]\].

A disease of global importance in public health affecting more than 100 tropical and subtropical countries. Recently there have been reports of epidemics in non-endemic areas of Europe and the United States where transmitter mosquitoes have possibly settled through infected travelers, enabling transmission cycles \[[@pone.0211401.ref002]\].

A recent study estimates there to be 390 million dengue infections every year, of which 96 million have clinical manifestations. The World Health Organization (WHO) estimated about 3.2 billion people worldwide in 2015 were in the probability of catching the disease \[[@pone.0211401.ref003],[@pone.0211401.ref004]\].

The increase in cases of dengue fever has made this disease an issue for society, but specifically for the health authorities due to the difficulties to control the epidemic caused by the dengue virus and insufficient health services to care for the affected population \[[@pone.0211401.ref005]\].

In this scenario, epidemiological surveillance has been an important tool for decision- making, aiming to provide useful evidence to enable decision-makers in health to lead and manage dengue cases/ policies more effectively \[[@pone.0211401.ref006]\].

The Objective of the study was to understand the current state of the art for both cost of illness and program studies, through a systematic review, which is important to support economic evaluations.

Methods {#sec006}
=======

Study design {#sec007}
------------

A systematic review of dengue cost analysis studies was carried out. It was developed by 2 researchers from the Faculty of Pharmacy (FF) of the Federal University of Goiás (UFG). The guiding question of the systematic review was: What is the cost of the dengue program and disease?

Search strategy and article selection {#sec008}
-------------------------------------

A search of the studies was conducted in the following databases: Medline (via PubMed), Virtual Health Library (VHL), The Cochrane Library and Center for Reviews and Dissemination (CRD). Only studies in English, Spanish and Portuguese were selected according to the Methodological Guideline: elaboration of a systematic review and meta-analysis of randomized clinical trials, as an attempt to increase the reproducibility of the study, since there is no guideline for systematic review in economic studies. \[[@pone.0211401.ref007]\].

A survey of the studies was carried out starting from 2005, due to a large number of dengue epidemics registered that year with a significant increase of serious cases and deaths in Brazil \[[@pone.0211401.ref008]\]. In addition, a systematic collection of publications mainly related to costs was made based on the last ten years \[[@pone.0211401.ref009]\]. The timeline and search strategy are shown in [Table 1](#pone.0211401.t001){ref-type="table"}.

10.1371/journal.pone.0211401.t001

###### Research strategy for the systematic review.
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  Database                                                                                                                                                                                                                                                                                                                                                                                                                                                          Search strategies                                           Timeline
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ---------------
  MEDLINE (via PubMed)                                                                                                                                                                                                                                                                                                                                                                                                                                              \"dengue\"\[MeSH Terms\] OR \"dengue\"\[All Fields\]) AND   02 October 15
  (\"economics\"\[Subheading\] OR \"economics\"\[All Fields\] OR \"cost\"\[All Fields\] OR \"costs and cost analysis\"\[MeSH Terms\] OR (\"costs\"\[All Fields\] AND \"cost\"\[All Fields\] AND \"analysis\"\[All Fields\]) OR \"costs and cost analysis\"\[All Fields\]) AND programme\[All Fields\]"                                                                                                                                                                                                                          
  (\"dengue\"\[MeSH Terms\] OR \"dengue\"\[All Fields\]) AND                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  (\"economics\"\[Subheading\] OR \"economics\"\[All Fields\] OR \"cost\"\[All Fields\] OR \"costs and cost analysis\"\[MeSH Terms\] OR (\"costs\"\[All Fields\] AND \"cost\"\[All Fields\] AND \"analysis\"\[All Fields\]) OR \"costs and cost analysis\"\[All Fields\]) AND (\"disease\"\[MeSH Terms\] OR \"disease\"\[All Fields\] OR \"diseases\"\[All Fields\]) OR (\"illness\"\[MeSH Terms\] OR \" illness \"\[All Fields\] OR \" illness \"\[All Fields\])                                                               
  VHL                                                                                                                                                                                                                                                                                                                                                                                                                                                               dengue AND cost AND program OR disease OR illness           21 June 16
  CRD                                                                                                                                                                                                                                                                                                                                                                                                                                                               (dengue) AND (program) OR (disease) OR (illness)OR (cost)   21 June 16

VHL: Virtual Health Library; CRD: Centre for Reviews and Dissemination.

After the search of the studies in the databases, a screening was conducted by reading the titles and abstracts, performed by the review team independently.

Searching for studies in all possible sources of data generates a much larger number of articles than would actually qualify for the established criteria. This is because the search strategy is elaborated by ensuring sensitivity over specificity. Thus, for the screening of studies, the sum of the total number of articles in all databases is recorded and the title is quickly read, allowing the selection of references and discarding a large number of references that do not fall under the eligibility criteria established by the Commission Review \[[@pone.0211401.ref007]\].

A free reference manager software, Mendeley, was used for sorting the articles, accounting of duplicates, organization of references, practicality and for optimization of time. The studies that went through the screening had their full text recovered. The eligibility of the studies was confirmed after reading the full text and selecting observational studies (case-control, cohort and cross-sectional) that presented economic evaluations, costs of dengue, program or illness, considered populations at risk for dengue disease, had no limit of sex, race or age, and the outcome in unit monetary policy. We excluded studies that presented proposals for new prevention measures, assuming the cost that could generate ([S1 Table](#pone.0211401.s002){ref-type="supplementary-material"}).

The selection of the studies and the screening were performed independently by two researchers and the results were compared. Disagreements in 15% of the documents were resolved in consensus meetings by arbitration through a third party investigator, when necessary.

Data extraction {#sec009}
---------------

The two researchers, who independently assessed the compliance of the full texts with the inclusion criteria, knew the names of the authors, institutions, year and scientific journals when they applied the eligibility criteria.

A data extraction form was prepared and was used for this purpose. The form was divided into 3 sections, according to the types of information provided by the studies:

-   Section A---General information about selected studies ([Table 2](#pone.0211401.t002){ref-type="table"}).

10.1371/journal.pone.0211401.t002

###### Section A- general information about selected studies.
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  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author/ Year publication                           Cost analysis (illness / program)   Sources of funding   What sources of funding
  -------------------------------------------------------- ----------------------------------- -------------------- ----------------------------------------------------------------------------------------------------------------------------
  Adriana Rodríguez, 2012 \[[@pone.0211401.ref014]\]       Cost of illness                     No                   \-

  Alessandra A. Machaof, 2014 \[[@pone.0211401.ref015]\]   Cost of illness                     No                   \-

  Blas Armien, 2008 \[[@pone.0211401.ref016]\]             Cost of illness/ program            Yes                  Pediatric Dengue Vaccine Initiative (PDVI)

  Carlos A. R. Pereira, 2014 \[[@pone.0211401.ref017]\]    Cost of illness                     No                   \-

  Donald S. Shepard, 2011 \[[@pone.0211401.ref018]\]       Cost of illness                     Yes                  Sanofi Pasteur

  Donald S. Shepard, 2012 \[[@pone.0211401.ref019]\]       cost of illness                     Yes                  Sanofi Pasteur

  Donald S. Shepard, 2014 \[[@pone.0211401.ref020]\]       Cost of illness                     Yes                  Sanofi Pasteur

  Donald S. Shepard, 2016 \[[@pone.0211401.ref021]\]       Cost of illness                     Yes                  Sanofi Pasteur

  Eduardo A. Undurraga, 2015 \[[@pone.0211401.ref022]\]    Cost of illness / program           Yes                  Sanofi Pasteur and Brandeis University and was also partially\
                                                                                                                    supports of the UBS Optimus Foundation

  Frances E. Edillo, 2015 \[[@pone.0211401.ref023]\]       Cost of illness                     Yes                  Sanofi Pasteur, The Global Emerging Infection Surveillance and Response System

  Frederic W. Selck, 2014 \[[@pone.0211401.ref024]\]       cost of illness                     No                   \-

  Hans-Christian Stahl, 2013 \[[@pone.0211401.ref025]\]    Cost of illness/ program            No                   \-

  Helena Taliberti, 2010 \[[@pone.0211401.ref026]\]        Cost of illness                     No                   \-

  Jose A. Suaya, 2009 \[[@pone.0211401.ref027]\]           Cost of program                     Yes                  Pediatric Dengue Vaccine Initiative (PDVI)

  Julien Beauté, 2010 \[[@pone.0211401.ref028]\]           Cost of illness /program            No                   \-

  Neil Thalagala, 2016 \[[@pone.0211401.ref029]\]          Cost of illness/ program            Yes                  International Research Consortium on Dengue Risk Assessment, Management, and Surveillance

  Pankaj Garg, 2008 \[[@pone.0211401.ref030]\]             Cost of illness                     No                   \-

  Pham Thi Tam, 2012 \[[@pone.0211401.ref031]\]            Cost of illness                     Yes                  Australian Non-Government Organisation Cooperation Program

  Raúl C. Rodríguez, 2016 \[[@pone.0211401.ref032]\]       Cost of illness                     Yes                  Sanofi Pasteur

  Sandra M. Santos, 2015 \[[@pone.0211401.ref033]\]        Cost of program                     Yes                  National Council for Scientific and Technological Development (CNPq)/ Ministry of Science, Technology and Innovation(MICT)

  Sonia Tarragona, 2012 \[[@pone.0211401.ref034]\]         Cost of illness                     No                   \-

  Uhart M., 2016 \[[@pone.0211401.ref035]\]                Cost of illness                     Yes                  Sanofi Pasteur
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

-   Section B---Information on study design, population included and comparators used (study methodology) ([Table 3](#pone.0211401.t003){ref-type="table"}).

10.1371/journal.pone.0211401.t003

###### Section B---Information on study population included and comparators used (study methodology).
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  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author/ Year publication                          Study population                                                                                                  Cost components included in the economical evaluation                                              Study period   Method of collecting cost data (gross or micro)
  ------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- -------------- -------------------------------------------------
  Adriana Rodríguez, 2012 \[[@pone.0211401.ref014]\]      Santiago de Cuba                                                                                                  Direct and indirect costs (Hospitalization and Ambulatory)                                         2006--2007     Micro costing

  Alessandra A., 2014 \[[@pone.0211401.ref015]\]          Brazil                                                                                                            Direct costs (Hospitalization)                                                                     2010           Micro costing

  Blas Armie, 2008 \[[@pone.0211401.ref016]\]             Panama                                                                                                            Direct and indirect costs (hospitalization/ Ambulatory)                                            2005           Gross costing

  Carlos A. R. Pereira, 2014 \[[@pone.0211401.ref017]\]   Brazil                                                                                                            Direct and indirect costs (Hospitalization and Ambulatory)                                         2011           Gross costing

  Donald S. Shepard, 2011 \[[@pone.0211401.ref018]\]      North America, Central America and Mexico, the Andean region, Brazil, the Southern Coneand the Caribbean region   Direct and indirect costs (Hospitalization and Ambulatory)                                         2000--2007     Micro costing

  Donald S. Shepard, 2012 \[[@pone.0211401.ref019]\]      Sri Lanka                                                                                                         Direct and indirect costs (Hospitalization and Ambulatory)                                         2009           Gross costing

  Donald S. Shepard, 2014 \[[@pone.0211401.ref020]\]      India                                                                                                             Direct costs (Hospitalization and Ambulatory)                                                      2006--2012     Gross costing

  Donald S. Shepard, 2016 \[[@pone.0211401.ref021]\]      World                                                                                                             Direct and indirect costs                                                                          2013           Gross costing

  Eduardo A. Undurraga, 2015 \[[@pone.0211401.ref022]\]   Mexico                                                                                                            Direct costs (disease and vector control)                                                          2010--2011     Micro costing

  Frances E. Edillo, 2015 \[[@pone.0211401.ref023]\]      Philippines                                                                                                       Ambulatory public and private costs, public and private hospital costs of DF and DHF, total cost   2008--2012     Micro costing

  Frederic W. Selck, 2014 \[[@pone.0211401.ref024]\]      World                                                                                                             Direct and indirect costs (Hospitalization and Ambulatory)                                         2011           Gross costing

  Hans-Christian Stahl, 2013 \[[@pone.0211401.ref025]\]   Peru, The Dominican Republic, Vietnam and Indonesia                                                               Direct and indirect costs (Hospitalization, Ambulatory, vector control)                            2011           Gross costing

  Helena Taliberti, 2010 \[[@pone.0211401.ref026]\]       Brazil                                                                                                            Direct costs (vector control)                                                                      2005           Gross costing

  Jose A. Suaya, 2009 \[[@pone.0211401.ref027]\]          Americas\                                                                                                         Direct and indirect costs (Hospitalization and Ambulatory)                                         2005           Gross costing
                                                          and Asia\                                                                                                                                                                                                                           

  Julien Beauté, 2010 \[[@pone.0211401.ref028]\]          Cambodia                                                                                                          Direct costs, Dalys                                                                                2006--2008     Micro costing

  Neil Thalagala, 2016 \[[@pone.0211401.ref029]\]         Sri Lanka                                                                                                         Direct cost vector control and direct costs (hospitalization)                                      2010--2012     Micro costing

  Pankaj Garg, 2008 \[[@pone.0211401.ref030]\]            India                                                                                                             Direct costs (Hospitalization)                                                                     2006           Micro costing

  Pham Thi Tam, 2012 \[[@pone.0211401.ref031]\]           Vietnam                                                                                                           Direct and indirect costs (Hospitalization and Ambulatory)                                         2006--2007     Gross costing

  Raúl C. Rodríguez, 2016 \[[@pone.0211401.ref032]\]      Colombia                                                                                                          Direct and indirect costs (Hospitalization and Ambulatory)                                         2010--2012     Gross costing

  Sandra M. Santos, 2015 \[[@pone.0211401.ref033]\]       Brazil                                                                                                            Direct costs (vector control)                                                                      2009--2010     Micro costing

  Sonia Tarragona, 2012 \[[@pone.0211401.ref034]\]        Argentina                                                                                                         Direct and indirect costs (Hospitalization and Ambulatory)                                         2009           Gross costing

  Uhart M., 2016 \[[@pone.0211401.ref035]\]               District of France                                                                                                Direct costs (Hospitalization)                                                                     2007--2011     Gross costing
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

-   Section C---Information from the perspective of the study, and addition of cost result in dollar PPP in the year 2015 ([Table 4](#pone.0211401.t004){ref-type="table"}).

10.1371/journal.pone.0211401.t004

###### Section C---Information on costs, specifying the types of costs (study outcome).
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  First author/ Year publication                           Study perspective                    Conversion PPP dollars (2015)
  -------------------------------------------------------- ------------------------------------ ----------------------------------
  Adriana Rodríguez, 2012 \[[@pone.0211401.ref012]\]       The public health service provider   17,46 million
  Alessandra A. Machaof, 2014 \[[@pone.0211401.ref013]\]   The public health service provider   286.52 thousand
  Blas Armien, 2008 \[[@pone.0211401.ref014]\]             The public health service provider   42.2 million
  Carlos A. R. Pereira, 2014 \[[@pone.0211401.ref015]\]    Society                              44.29 thousand
  Donald S. Shepard, 2012 \[[@pone.0211401.ref017]\]       Society                              162.04 million
  Donald S. Shepard, 2014 \[[@pone.0211401.ref018]\]       The public health service provider   2.16 billion
  Eduardo A. Undurraga, 2015 \[[@pone.0211401.ref020]\]    Society                              33.4 million
  Frances E. Edillo, 2015 \[[@pone.0211401.ref021]\]       The public health service provider   151.62 million
  Hans-Christian Stahl, 2013 \[[@pone.0211401.ref023]\]    Society                              Vietnam 7.57 million
  Helena Taliberti, 2010                                   Payer perspective                    Indonesia 4.05 million
  Jose A. Suaya, 2009                                      Society                              Peru 1.53 million
  Julien Beauté, 2010                                      Society                              Dominican Republic 20.47 million
  Helena Taliberti, 2010 \[[@pone.0211401.ref024]\]        The public health service provider   20,82 million
  Julien Beauté, 2010 \[[@pone.0211401.ref026]\]           The public health service provider   15,27 million
  Neil Thalagala, 2016 \[[@pone.0211401.ref027]\]          The public health service provider   13.61 million
  Pankaj Garg, 2008 \[[@pone.0211401.ref028]\]             Society                              132.58 million
  Pham Thi Tam, 2012 \[[@pone.0211401.ref029]\]            Society                              82.9/ per patient
  Raúl C. Rodríguez, 2016 \[[@pone.0211401.ref030]\]       Society                              216.25 million
  Sandra M. Santos, 2015 \[[@pone.0211401.ref031]\]        The public health service provider   551.01
  Sonia Tarragona, 2012 \[[@pone.0211401.ref032]\]         Society                              11.59 million
  Uhart M., 2016 \[[@pone.0211401.ref033]\]                Payer perspective                    7.87 million

The data was extracted and arranged into tables in the excel program in a standardized and methodological way to allow specification of the cost informed. This grouping was performed to facilitate the comparative analysis of the studies, favoring the identification of the variability between them.

Quality assessment {#sec010}
------------------

The quality of a systematic review depends on the validity of the studies included in it, so at this stage of the quality assessment of each study it is important to consider all possible sources of error (bias) in order to generate results that may be reliable \[[@pone.0211401.ref010]\].

For health cost analysis, a checklist was developed based on the protocol proposed by the British Medical Journal (BMJ), and on the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) in 2013 by the International Society for Pharmacology and Outcomes Research (ISPOR) \[[@pone.0211401.ref011],[@pone.0211401.ref012]\].

The BMJ checklist allows to evaluate the items of a health economic evaluation, while the CHEERS checklist has 24 items that should ideally be present in the publications of studies on economic evaluation in health, but was not created to be an instrument of evaluation of methodological quality in addition. Both of them present flaws in the fact that they always relate clinical efficacy to new alternative interventions.

Therefore, the elaborated checklist contains 29 items ([Table 5](#pone.0211401.t005){ref-type="table"}) which address the main points that characterize a health cost analysis. The initial objective of this checklist was to provide guidelines for the evaluation of articles submitted to the BMJ, enabling easier understanding of experts and non-specialist. This checklist is divided into three blocks of questions: i) drawing the study with 11 items; ii) data collection holding 9 items; And iii) analysis and interpretation of the results holding 9 items. The application of this quality instrument in this work was performed independently between the two reviewers. The discrepancies were solved by consensus and, in the absence of consensus, a third reviewer was consulted.

10.1371/journal.pone.0211401.t005

###### Checklist economic evaluation.
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  Item                                                                                YES   \%
  ----------------------------------------------------------------------------------- ----- -----
  **Drawing the Study**                                                                     
  Research is adequate                                                                22    100
  The epidemiological source is stated                                                22    100
  The study is identified as an economic evaluation                                   22    100
  Provide a structured summary                                                        13    60
  Describe characteristics of population                                              13    60
  Time horizon                                                                        11    50
  Study perspective                                                                   17    80
  The form of economic evaluation used is stated                                      14    64
  The study was approved by an institution authorized in ethics in research           20    91
  Conflicts of interest                                                               12    55
  Study funded                                                                        13    59
  **Data Collection**                                                                       
  The source(s) of costs estimates used are stated                                    19    86
  The costs were clearly described                                                    19    86
  The valuation method is stated                                                      12    55
  Type of cost is stated                                                              22    100
  Currency, price date, and conversion                                                11    50
  Unit costs are described in                                                         11    50
  The analytical model used is stated                                                 11    50
  Methods and assumptions for extrapolating results                                   11    50
  The measurement of costs is adequate                                                18    81
  **Analysis and Interpretation of the Results**                                            
  Evidence of quality                                                                 18    81
  Characterizing uncertainty                                                          11    50
  Outcome measures in health were clearly described, relevant to the study question   19    86
  Ratio between health costs and outcomes                                             13    59
  The approach to sensitivity analysis is given                                       13    59
  Relevant aspects                                                                    11    50
  The variation of costs over time is justified                                       13    59
  Conclusions follow from the data reported                                           21    95
  Conclusions are accompanied by the appropriate caveats                              20    91

The checklist established three rating grades for the items: \"Yes,\" \"No,\" and \"Not applicable.\" At the end of the classification, a relative value of each of these grades was settled for each study. The goal was to check the percentages of \"Yes\" for each question.

Data analysis and interpretation {#sec011}
--------------------------------

The profile of the studies and their characteristics were presented in tables, in order to allow comparison of the selected parameters, as well as the costs. This financial aspect was evaluated through the results in monetary amounts associated with the disease and the program.

The methodological variability of the monetary values limits the comparability of data, so a conversion of monetary values was performed in the concept of Purchasing Power Parity (PPP). PPP is an artificial currency also denominated \"international dollars\", which eliminates the differences of the countries and allows the income to be expressed in a common artificial currency \[[@pone.0211401.ref013]\].

All annual values reported in the studies were converted to the local currency at the exchange rate of the year of study. The value of the local currency has been inflated to 2015 with each country\'s Consumer Price Index (CPI), by <http://fxtop.com/en/inflation>.

After the values were corrected for inflation, the PPP was applied to the conversion rate in dollars PPP by <http://data.worldbank.org/indicator/PA.NUS.PPP>, to allow a greater comparison of the results. For studies that presented more than one annual value, an average was made between the years, always choosing the last year of the study to carry out the conversion ([S2 Table](#pone.0211401.s003){ref-type="supplementary-material"}).

Results {#sec012}
=======

The systematic review of costs of dengue, began in September 2015, in the Medline (via Pubmed), VHL, CRD databases, found 665 references. Of these, 56 were selected initially by titles and abstracts. After the removal of duplicates, 50 references remained. After analyzing full texts, 22 articles \[[@pone.0211401.ref014]--[@pone.0211401.ref035]\] were selected, according to the inclusion criteria previously established ([Fig 1](#pone.0211401.g001){ref-type="fig"}). The reason for exclusion in the last step has been declared ([S1 Table](#pone.0211401.s002){ref-type="supplementary-material"}).

![Flowchart of the selection of the studies included in the systematic review.](pone.0211401.g001){#pone.0211401.g001}

VHS: Virtual Health Library; CRD: Centre for Reviews and Dissemination.

The 22 studies were published as of 2005, of which seven (32%) were published in 2016. Only two studies (9%) analyzed only the cost of the program, fourteen studies (64%) only cost the disease, and six studies (27%) analyzed both costs ([Table 2](#pone.0211401.t002){ref-type="table"}).

Twelve (55%) studies reported financial support, of which eight (36%) reported financial support from the Pharmaceutical Industry ([Table 2](#pone.0211401.t002){ref-type="table"}).

After analyzing the general information of the selected studies, [Table 2](#pone.0211401.t002){ref-type="table"} goes to section A which shows information about study design, population included and comparators used (study methodology).

The time horizon of major analysis was 7 years \[[@pone.0211401.ref026]\], but only the last 3 years of this article were considered, the average time of analysis of the articles was of 1 year. Four (18%) studies have Brazil as the target population ([Table 2](#pone.0211401.t002){ref-type="table"}).

The method for collecting cost data consisted of 10 studies (45%) of micro-costing and 12 (55%) of gross-costing ([Table 3](#pone.0211401.t003){ref-type="table"}).

The cost components included in the economic evaluation were based on direct and indirect costs, of which 12 (55%) included both costs ([Table 3](#pone.0211401.t003){ref-type="table"}).

The incidence of the disease in the period studied was considered in all studies (100%) ([Table 3](#pone.0211401.t003){ref-type="table"}).

Twelve studies (55%) adopted the perspective of society, while ten studies (45%) used the perspective of the public health service provider, or a private budget holder ([Table 4](#pone.0211401.t004){ref-type="table"}).

Four studies \[[@pone.0211401.ref018]; [@pone.0211401.ref020]; [@pone.0211401.ref024]; [@pone.0211401.ref027]\] were not able to calculate the cost in dollars PPP in 2015, since they bring in their results costs of several localities of the world, making difficult to realize the inflation in the local currency. All four studies adopted perspective of society and their respective costs were US \$ 1.8 billion in 2005 \[[@pone.0211401.ref027]\]; US \$ 3.1 billion in 2007 \[[@pone.0211401.ref018]\]; US \$ 40 billion in 2011 \[[@pone.0211401.ref024]\]; US \$ 8.9 billion in 2013 \[[@pone.0211401.ref021]\].

In the comparison of monetary costs between the studies ([Table 4](#pone.0211401.t004){ref-type="table"}), emerging countries as India had expenditures of 4.69 billion dollars PPP in direct medical costs (outpatient / hospital). Whereas Brazil spent 20.82 million dollars PPP in direct cost of prevention and control of *Aedes aegypti*. France, a developed country, spent 15 million dollars PPP on direct medical costs of hospitalization.

Two studies (9%) brought an analysis of intangible costs, represented by the Quality- Adjusted Life Years (QALY). In Panama \[[@pone.0211401.ref016]\] there was an average of 67% QALY during the worst days of illness in 2005, while in Malaysia \[[@pone.0211401.ref019]\] the average was 60% QALY in 2009. And three studies (14%) brought indirect cost analysis, represented by the Disability-Adjusted Life Years (DALYs). In Mexico \[[@pone.0211401.ref022]\] the annual disease rate averaged 65 DALYs per million inhabitants between 2010 and 2011. In Cambodia \[[@pone.0211401.ref028]\] the annual disease rate ranged from 24,3 to 100,6 DALYs per hundred thousand inhabitants between 2007 and 2008. The Americas presented an estimated 73,000 DALYs, with 131 DALYs per million inhabitants in 2004, the highest number per million inhabitants \[[@pone.0211401.ref018]\].

The performance of the studies in comparison to the checklist economic evaluation is satisfactory. All the studies contained more than 50% of the items required in total checklist ([Table 5](#pone.0211401.t005){ref-type="table"}).

The most complete study reported 90% \[[@pone.0211401.ref022]\] of 'Yes' to the items present in the checklist, and the most incomplete study reported on the checklist of 29 items elaborated to evaluate the quality of economic evaluation studies 50% \[[@pone.0211401.ref014]\] of 'Yes'.

From the items checked, in the first block that deals with the study design, all the studies are identified as an economic evaluation, but the structure of the abstracts in 9 studies was not appropriate, such as the presentation of objectives, perspective, methodology and results ([Table 5](#pone.0211401.t005){ref-type="table"}).

In the second block, data collection was verified. The cost measurement is given in 86% of the studies, however, currency price readjustments for inflation or currency conversion, for the costs that were collected in different periods, were found in only 50% of the studies.

In the third block, data analysis and interpretation was determined, and 9 studies (41%) did not address sensitivity, while 11 studies (50%) did not correct methodological uncertainty, but all conclusions result from reported data, accompanied by 21 studies (95%) with appropriate warnings.

To sum up authors\' conclusions regarding the cost found, costs of dengue are of great impact on the economy, and further studies are needed with a more accurate estimate for the decision makers. Therefore, carrying out this systematic review is of utter necessity.

Discussion {#sec013}
==========

Methodological comparison between studies {#sec014}
-----------------------------------------

Dengue is an acute illness and the incidence is its epidemiological measure \[[@pone.0211401.ref034]\], this factor is shown on all studies, leading to cost analysis over time and an evaluation of the effectiveness of intervention strategies, as they are based on cost of disease in a given year of study \[[@pone.0211401.ref036];[@pone.0211401.ref037];[@pone.0211401.ref038]\].

The studies included in the SR are recent, from 2005 on, which indicates that these studies of costs of dengue may be of growing interest for the inclusion of preventive interventions. One example is the dengue vaccine, which in recent years has arisen several candidates in pre-clinical and clinical developmental stages against the four serotypes of the dengue virus \[[@pone.0211401.ref039]; [@pone.0211401.ref040]\] an example is Dengvaxia (CYD-TDV) from Sanofi Pasteur, the first live quadrivalent recombinant live vaccine registered in 2015 \[[@pone.0211401.ref041]\]. WHO recommends the inclusion of such intervention to countries that present epidemiological data indicating the economic burden of the disease \[[@pone.0211401.ref041]\], thus using these SR studies for cost-effectiveness calculations \[[@pone.0211401.ref038]\].

Amongst the identified studies, there was a great methodological variation of the costs found due to the influence of the methodological choices. In the 20 economic studies identified, they are directly related to dengue costs, but the method of costing and the composition of cost items differentiate from one study to the other, the form of micro-costing and gross-costing.

In the SR of Ernstsson and colleagues regarding the cost of multiple sclerosis disease, researchers also faced methodological differences in the inclusion of different types of costs \[[@pone.0211401.ref042]\]. It can be concluded that the calculation methods directly affect the comparability between the studies.

The time horizon of the economic evaluation of all the costs that are relevant to the desired results should be made explicit and justified in its methodology \[[@pone.0211401.ref043]\]. In twelve papers the time horizon was not made explicit, but that did not compromise the evidence of the data collected, since it was possible to obtain the period of data collection after the studies.

An analyze of the methodology used in these articles were identified specific questions relevant to the study of dengue costs, such as the definition of the study perspective, which can greatly cause variation in the results obtained \[[@pone.0211401.ref041]\]. The studies did not use only one perspective, but the perspective by the managing body as buyer of public and private health services, when approached from the perspective of the society most of the studies brought all the costs of the production of the service /procedure and the time wasted by the patients and their families, in addition to costs related to loss of productivity and premature death.

Thus, the economic analysis from the perspective of society brings an additional analysis, including not only an assessment of health costs, but also a measurement of the health consequences caused by dengue.

The measurement of these consequences can go beyond mortality and morbidity. The measurement of health-related quality of life, an evaluation that has increased significantly in the last 50 years, is recommended as the measurement of health outcome by international guidelines and by international health technology assessment agencies, such as NICE, the United Kingdom United \[[@pone.0211401.ref043]\].

In the articles, 1 \[[@pone.0211401.ref031]\] measured QALY, using EuroQol as a utility measure, and 7 articles \[[@pone.0211401.ref017];[@pone.0211401.ref018];[@pone.0211401.ref019];[@pone.0211401.ref020];[@pone.0211401.ref025];[@pone.0211401.ref026];[@pone.0211401.ref029]\] brought DALY, as an alternative to the use of QALY.

However, QALY is a broader and more complex indicator than DALY by incorporating quality of life beyond physical disability. The QALY and DALY values found were close to each other, unlike the analysis with the monetary value measurement \[[@pone.0211401.ref044]\].

The economic studies that bring in addition to COI, DALY and QALY, are the most appropriate studies for evaluating socially and financially viable public strategies \[[@pone.0211401.ref044]\].

Comparability of cost between studies {#sec015}
-------------------------------------

Andersson proposed a methodology for comparing drug prices, and one of the criteria established by Andersson is to select countries with similar parameters and health system characteristics \[[@pone.0211401.ref045]\].

For the present work, as it deals with costs of the disease and the program that involves the use of medication or prophylactic measures, the analysis criteria used the health systems to evaluate countries that presented the highest cost, and the country of lowest cost.

Developing countries that had the highest costs with dengue \[[@pone.0211401.ref019];[@pone.0211401.ref020];[@pone.0211401.ref021];[@pone.0211401.ref022];[@pone.0211401.ref023];[@pone.0211401.ref026]\], have common socioeconomic characteristics and similarities to health systems. Brazil and India, for example, have those similarities determined on their Constitution as an universal right \[[@pone.0211401.ref014];[@pone.0211401.ref046];[@pone.0211401.ref047]\]. India, being the second most populous country in the world, reported an annual average of 20,474 million cases of dengue fever, presenting the highest cost of the disease \[[@pone.0211401.ref014]\].

Argentina and Mexico presented similar costs, one of the main characteristics of both countries being the fragmentation of the health service systems, as well as its access to those services \[[@pone.0211401.ref048]\].

France as a developed country, presented the lowest expenditure. The French health service system was considered by the WHO close to being the best global healthcare, being largely financed by the government, the policy is centralized, further the state has the control of the activities of financial institutions, doctors and patients \[[@pone.0211401.ref049]\].

Conclusion {#sec016}
==========

Although there were methodological variations between the studies, the costs found within their perspectives analyzed in the included studies demonstrate that our results support that dengue has a great impact on the economy. The sum of dengue costs for the articles \[[@pone.0211401.ref014];[@pone.0211401.ref015];[@pone.0211401.ref016];[@pone.0211401.ref017];[@pone.0211401.ref019];[@pone.0211401.ref020];[@pone.0211401.ref022];[@pone.0211401.ref023];[@pone.0211401.ref025];[@pone.0211401.ref026];[@pone.0211401.ref028];[@pone.0211401.ref029];[@pone.0211401.ref030];[@pone.0211401.ref031];[@pone.0211401.ref032];[@pone.0211401.ref033];[@pone.0211401.ref034];[@pone.0211401.ref035]\] showed that 18 countries generated a cost of approximately US\$ 3.3 billion PPP in 2015.

Strengths and limitations {#sec017}
-------------------------

The SR, was performed at all stages independently by two authors, possible disagreements of relevant studies were discussed among the authors.

It is the first review of costs of Dengue, in addition to using an approach that relates the studies to the local health system, indicates the methodological differences, points out what should be done in a study of economic analysis in health and analyzes the presence of factors in the studies.

The method chosen for recalculating costs, PPP dollars, made it easier to compare the results of study costs, since there was standardization of results in a single year, 2015.

Properly analyzing the results of cost evaluations using the resource allocation of decision is not an easy task because the studies have the interference of the time factor, the incorporation of new technologies and the local epidemiological scenario \[[@pone.0211401.ref050]\].

Research has shown that dengue imposes a significant level of financial burden on families and caregivers \[[@pone.0211401.ref015];[@pone.0211401.ref016];[@pone.0211401.ref017];[@pone.0211401.ref018];[@pone.0211401.ref020];[@pone.0211401.ref021];[@pone.0211401.ref022];[@pone.0211401.ref023];[@pone.0211401.ref024];[@pone.0211401.ref025];[@pone.0211401.ref026];[@pone.0211401.ref027];[@pone.0211401.ref028];[@pone.0211401.ref030];[@pone.0211401.ref031];[@pone.0211401.ref033];[@pone.0211401.ref034]\] but not all studies that brought the general aspects, for example, aspects that evaluate loss of work productivity, Family expenses (indirect costs).

Therefore, the total costs of dengue including all parameters of indirect costs would be much higher than those estimated in this RS.

A possible bias in the research is 40% of the studies being funded by the Sanofi industry, but the fact that a research receives financial support from an entity that has a direct interest in the subject being studied does not necessarily imply that researchers\' conclusions are biased in all of these articles. It was presented the source of funding and passed the ethics committee in researches, being an acceptable practice and all studies funded by Sanofi have stated that there is no conflict of interest \[[@pone.0211401.ref051]\].

A survey including articles that use other types of analysis such as cost minimization may contribute to a more complete understanding of economic burden of Dengue \[[@pone.0211401.ref044]\].

Supporting information {#sec018}
======================

###### This is the PRISMA 2009 checklist.

(PDF)

###### 

Click here for additional data file.

###### Reason for exclusion, based on the stated inclusion criteria.

(TIF)

###### 

Click here for additional data file.

###### Conversion ppp dollar.

(TIF)

###### 

Click here for additional data file.
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